Investor Relations
The pace is accelerating. Not leveling off.
New blind validations, new patent filings, and new drug targets have landed roughly every two weeks this summer. We are raising now to match the pace of the science — and we are selective about who we bring in.
$157B
Investor Inquiries
Let's talk.
We respond to all serious inquiries within 48 hours. If you are a venture investor, family office, or strategic partner, fill out the form below.
Current addressable market in Oncology and Rare Disease — growing to $350B+ with Agriculture and Industrial
36/36
Blind predictions correct — cryptographically locked before literature was checked. 100% record.
7
USPTO provisional patents confirmed, priority chain from August 2025 through July 2026
4
Consecutive MAPK cancer pathway targets hit with a single molecular scaffold — no approved drug does this
"
Since we last spoke, HARMONY hasn't slowed down — it's compounded. New blind validations, new targets, and new filings have landed roughly every two weeks this summer.
Chase K. McMichael · Founder & CEO · July 2026